Details of the Drug Formulations

General Information of Drug (ID: DM7GCVW)

• Drug Name: Acalabrutinib Drug Info
• Synonyms: Calquence; UNII-I42748ELQW; I42748ELQW; Acalabrutinib [INN]; Acalabrutinib [USAN:INN]; Calquence (TN); Acalabrutinib(ACP196); Acalabrutinib (ACP-196); GTPL8912; Acalabrutinib (JAN/USAN/INN); SCHEMBL14637368; EX-A881; WDENQIQQYWYTPO-IBGZPJMESA-N; KS-000006AT; KS-000006AD; s8116; BDBM50175583; AKOS030526094; ZINC208774715; DB11703; CS-5356; DS-3326

Indication

Disease Entry	ICD 11	Status	REF
leukaemia	2A60-2B33	Approved	[1]
Mantle cell lymphoma	2A85.5	Approved	[2]
Chronic lymphocytic leukaemia	2A82.0	Phase 3	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[4]

• Cross-matching ID:
  PubChem CID: 71226662
  CAS Number: 1420477-60-6
  TTD ID: D09PQZ
  INTEDE ID: DR0031
  ACDINA ID: D00005

Full List of Drug Formulations Containing This Drug

Acalabrutinib 100 mg capsule

Company	Formulation ID	FDA Description
AstraZeneca	F00021	Fd&c blue no. 2; Magnesium stearate; Ferric oxide yellow; Titanium dioxide; Silicon dioxide; Cellulose, microcrystalline; Gelatin; Sodium starch glycolate type a potato; Starch, corn

References

• [1] FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 210259
• [2] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] ClinicalTrials.gov (NCT04346199) Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.. U.S. National Institutes of Health.